H.C. Wainwright lowered the firm’s price target on Century Therapeutics (IPSC) to $2 from $5 and keeps a Buy rating on the shares following the Q4 report. The firm cut the price target after CNTY-101 was discontinued in B cell lymphomas.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPSC:
- Century Therapeutics price target lowered to $7 from $11 at Chardan
- Century Therapeutics price target lowered to $5 from $12 at Guggenheim
- Century Therapeutics Reports 2024 Financial Results and Strategic Updates
- Century Therapeutics price target lowered to $2 from $4 at Piper Sandler
- Century Therapeutics Re-prioritizes Pipeline for Key Programs